We support personalized healthcare services
through the integration of biosignal
measurement technology and AI.

Left Circle Middle Circle Right Circle

Our Journey

Since its establishment in 2016, SCI has continued to drive technological innovation.
Based on software and AI·data-driven convergence technologies,
we have built differentiated R&D capabilities,
creating new value in the field of digital healthcare.

2025

  • Approved for exploratory clinical trials by the Ministry of Food and Drug Safety (MFDS)
  • Certified for Digital Medical Device GMP compliance
    (Digital Medical Device Software (AI/ML), Medical Device Hardware)
  • Selected for the Gwangju Dong-gu Healthcare Startup Support Program
  • Selected for the Deep Tech TIPS Global Marketing Program
  • Obtained manufacturing certification for a Class II medical device (Pulse Rate Monitor)
  • Patent registered (Blood glucose and blood pressure measurement device using a PPG sensor)

2024

  • Certified for Medical Device GMP compliance
  • Obtained manufacturing approval for a Class II medical device (Ballistocardiograph)
  • Licensed as a medical device manufacturer
  • Secured investment from Korea SMEs and Startups Agency (KOSME)

2023

  • Selected for the R&D Special Zone Promotion Program (Research Institute R&D Project)
  • Selected for the Deep Tech TIPS Program (KRW 1.5 billion over 3 years)
  • Conducted an analytical clinical study on a PPG-based blood glucose monitoring system
  • Designated as a Venture Nara product by the Public Procurement Service (EDL-1004)
  • Completed clinical trials for a Class II medical device (Ballistocardiograph)
  • KC certification for a non-invasive AI-based healthcare support device
  • Filed patent application for a PPG-based glucose and blood pressure monitoring device for pets
  • Registered patent for a blood pressure measurement device using ballistocardiography and AI technology

2021-22

  • Secured investment from the Jeonnam Angel Investment Matching Fund
  • Registered a patent for a fall prediction method using ballistocardiography and camera-based sensing
  • Achieved ISO 13485 certification for ballistocardiography devices and healthcare solutions
  • Registered a patent for a diabetes prediction method and system using ballistocardiography signals
  • Registered a patent for an arrhythmia prediction method and system using ballistocardiography signals
  • Registered a patent for a hypertension prediction method and system using machine learning
  • Relocated headquarters from Jangseong to Gwangju
  • Published a research paper on glucose level prediction using PPG and machine learning
  • Selected as a Kibo-Star Valley company

2017-18

  • Relocated headquarters from Gwangyang to Jangseong
  • Registered a patent for a non-contact biosignal-based patient monitoring method
  • Registered a patent for a fall prevention bed
  • Registered a patent for a smart pillow system

2016

  • Founded Software Convergence Institute Co., Ltd.
  • Developed the EDL-1004 pilot system

logo_white

Business Name Software Convergence Institute CEO Park Cheol Gu
Head Office Room 205-2, Building 2, 333 Cheomdangwagi-ro, Buk-gu, Gwangju 61008, Korea 
Branch Office
 Room 404, Building 2, Gwangju AI Startup Camp, 193-12 Geumnam-ro, Dong-gu, Gwangju 61472, Korea
E-commerce Registration Number 2024-광주북구-0441 Business Registration Number 758-87-00323  
TEL
 1600-0415 Email pck3867@scikorea.co.kr

Business Name Software Convergence Institute CEO Park Cheol Gu
Head Office 광주시 북구 첨단과기로 333, 사업화2동 205-2호

Branch Office
 광주시 동구 금남로 193-12 광주 AI창업캠프 2호관 404호
E-commerce Registration Number 2024-광주북구-0441 
Business Registration Number 758-87-00323  

TEL
 1600-0415 Email pck3867@scikorea.co.kr

Copyrightⓒ2026 Software Convergence Institute. All rights reserved.

Copyrightⓒ2026
(주)소프트웨어융합연구소.
All rights reserved.